Brought to you by 
Avid Radiopharmaceuticals brings in $26mm through Series C
05 Jun 2007
Executive Summary
Avid Radiopharmaceuticals, a molecular imaging company investigating agents that detect and monitor amyloid plaques in Alzheimer's disease patients, raised $26mm in its Series C financing. New backers Safeguard Scientifics, which contributed $7.3mm, and AllianceBernstein co-led the round. Earlier investors Pfizer Strategic Investments Group, Lilly Ventures, RK Venture Group, and BioAdvance also participated. A Safeguard Scientifics executive joins Avid's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Avid Radiopharmaceuticals brings in $26mm through Series C
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice